{"id":"W3147445522","doi":"10.1016/s1556-0864(21)01939-0","title":"97O First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"ca_institutions":"Kingston General Hospital","funders":"Chugai Pharmaceutical; Genentech; Ipsen; Ono Pharmaceutical; Astellas Pharma; F. Hoffmann-La Roche; Sanofi; Servier; Amgen; Pfizer; Les Laboratories Pierre Fabre; PharmaMar; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Pembrolizumab; Oncology; Internal medicine; Chemotherapy; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006100665,0.0002952458,0.0007628887,0.0003356518,0.0003976968,0.0008245238,0.0002986652,0.0004584252,0.002678702],"category_scores_gemma":[0.0005856304,0.0001775109,0.001123779,0.0005245241,0.0001486972,0.0007392203,0.0003667409,0.0009976455,0.0008228582],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006949814,"about_ca_system_score_gemma":0.0005975062,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002198374,"about_ca_topic_score_gemma":0.003111751,"domain_scores_codex":[0.9996929,0.00003496414,0.00002114254,0.00007407487,0.00006145205,0.0001155181],"domain_scores_gemma":[0.9997137,0.00004375421,0.00007724008,0.00003268107,0.0000341932,0.00009845176],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1702503,0.006003508,0.4749995,0.0007275182,0.003909572,0.001214746,0.0002118416,0.00167407,0.01023197,0.000231444,0.01433146,0.3162141],"study_design_scores_gemma":[0.01197993,0.03130226,0.9334852,0.0001722094,0.002861065,0.00084029,0.0001548349,0.0009463604,0.002382711,0.0002649119,0.01555984,0.00005041694],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.980998,0.005930732,0.000319258,0.000360108,0.0001764347,0.0002183216,0.005697293,0.00004576059,0.006254102],"genre_scores_gemma":[0.9810844,0.002379612,0.0002399631,0.0006936379,0.0001354778,0.0001420874,0.01090841,0.00001458761,0.004401886],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002678702,"threshold_uncertainty_score":0.008961141,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01521667397962573,"score_gpt":0.3473521490314572,"score_spread":0.3321354750518315,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}